Skip to main content
. 2021 Dec 4;15(4):771–777. doi: 10.1093/ckj/sfab244

Table 4.

Changes in kidney function, proteinuria and haematuria after the withdrawal of CS + MPAA treatment (N = 21)

Characteristics Last visit with CS + MPAA treatment End of follow-up
eGFR (mL/min/1.73 m2), median (IQR) 64.0 (38.4–90.0) 54.0 (19.0–80.0)*
Proteinuria (g/day), median (IQR) 0.6 (0.3–1.1) 0.7 (0.3–1.5)
Patients with haematuria, n (%) 12 (57.1) 14 (66.7)

*P = 0.002.